The Medicines Company (MDCO) recently reported top-line pivotal data on its siRNA candidate inclisiran, which targets the PCSK9 (proprotein convertase subtilisin/kexin type 9) pathway for lowering cholesterol. According to MDCO, inclisiran reduces levels of LDL cholesterol with just two injections annually. As a premium courier, Yourway functions as the backbone of the supply chain, allowing new therapies to reach patients more efficiently.